26
+8.33%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Modalis Therapeutics
Its shares trade on Tokyo Stock Exchange under the ticker 4883.T. It has been listed since 3 August 2020. In the fiscal year to 31 December 2022, it reported revenue of ¥40.5m and a net loss of ¥2.70bn. At that date it held total assets of ¥3.13bn and shareholders' equity of ¥2.94bn.
Modalis Therapeutics Corp. engages in the development of gene therapy drugs. The company is headquartered in Chuo-Ku, Tokyo-To. The company went IPO on 2020-08-03. The firm develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The firm has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The firm's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 3 Aug 2020
- Employees
- 36
- Website
- modalistx.com ↗
Leadership
Pay as last reported
- Mr. Haru MoritaPresident, Chief Executive Officer, Founder, CEO of Subsidiary, Representative Director, since 2016
- Mr. Naoki KobayashiChief Financial Officer, Vice President, Executive Officer
- Mr. Tetsuya YamagataSenior Vice President, Chief Scientific Officer, since 2021
- Dr. Seth LevyExecutive Officer, VP of Manufacturing
- Dr. Yuanbo QinExecutive Officer, VP of Neuromuscular Diseases
- Mr. Toshio FurutaIndependent Director, since 2018
- Dr. Joseph MccrackenIndependent Director, since 2018
- Ms. Miyuki ShimaneIndependent Director, since 2018
- Mr. Teruhisa TajimaIndependent Director, since 2018
- Mr. Hideki TakedaIndependent Director, since 2016
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Develops gene therapy drugs using CRISPR-GNDM technology for genetic diseases and epigenetics.
- Operates two business models: collaborative and in-house pipelines.
- Has a pipeline with 5 collaborative and 2 in-house drug development items.
Weaknesses
- Limited to 36 full-time employees.
- IPO occurred in 2020, indicating a relatively new company.
- Relies on CRISPR-GNDM technology, which may face regulatory or technical challenges.
Opportunities
- Expanding the collaborative model by partnering with other firms for drug development.
- Growing demand for gene therapy treatments for genetic diseases.
- Potential to develop more in-house therapeutic agents using CRISPR-GNDM technology.
Threats
- Regulatory hurdles for gene therapy drugs in the healthcare sector.
- Competition in the biotechnology industry for CRISPR-based therapies.
- Dependence on a single technology platform (CRISPR-GNDM) for all drug development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.